Abstract
Erythropoietin (EPO) is a hypoxia-inducible hormone best known for its role in erythropoiesis. However, EPO also has anti-inflammatory and tissue-protective characteristics in multiple organs as summarised in this review. In the brain, EPO is upregulated by hypoxia, regulates ventilation and plays a key role in neuroprotection and neuroplasticity. Systemically administered EPO crosses the blood-brain-barrier, enhances neuroplasticity and improves cognitive functions in several disorders of the brain. Given this evidence, a trial is being planned to investigate whether EPO can improve the physiologic and neurologic outcome of COVID-19.
| Bidragets oversatte titel | Erythropoietin as possible treatment of brain diseases |
|---|---|
| Originalsprog | Dansk |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 182 |
| Udgave nummer | 44 |
| ISSN | 0041-5782 |
| Status | Udgivet - 26 okt. 2020 |
Emneord
- Betacoronavirus
- Brain/metabolism
- Brain Diseases/drug therapy
- Coronavirus Infections/drug therapy
- Erythropoietin/therapeutic use
- Humans
- Pandemics
- Pneumonia, Viral/drug therapy
Fingeraftryk
Dyk ned i forskningsemnerne om 'Erythropoietin as possible treatment of brain diseases'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS